Bionet

Bionet Interest Coverage

The Interest Coverage Ratio of Bionet (1784.TWO) as of Nov 2, 2026 is 1.96. In the previous year, Interest Coverage Ratio was 6.48 — a change of -69.77% (lower).

Interest Coverage

1.96

YoY

-69.77%

Last updated:

Interest Coverage Ratio of Bionet is 2024 1.96 . Interest Coverage Ratio of Bionet was 2023 6.48 . It decreases by -69.77% lower compared to the previous year.

The Bionet Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-0.63 TWD
Jan 1, 2018
4.00 TWD
Jan 1, 2019
0.79 TWD
Jan 1, 2020
2.28 TWD
Jan 1, 2021
9.11 TWD
Jan 1, 2022
7.84 TWD
Jan 1, 2023
6.48 TWD
Jan 1, 2024
1.96 TWD
The Bionet Interest Coverage history
YEARInterest CoverageYoY
1.96-69.77%
6.48-17.34%
7.84-13.92%
9.11+300.01%
2.28+187.84%
0.79-80.20%
4.00-732.76%
-0.63-76.90%
-2.73+3,405.03%
-0.08-55.00%
-0.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

Interest Coverage Ratio of Bionet is 1.96 in 2024.

Interest Coverage Ratio of Bionet changed from 6.48 to 1.96, representing a -69.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Bionet since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Bionet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bionet

All Key Metrics — Bionet